Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect
Research output: Contribution to journal › Letter › Research › peer-review
Standard
Pseudohyperaldosteroism during itraconazole treatment : a hitherto neglected clinically significant side effect. / Brandi, Sandra L.; Feltoft, Claus L.; Serup, Jørgen; Eldrup, Ebbe.
In: Drug and Therapeutics Bulletin, Vol. 61, No. 3, 2023, p. 44-47.Research output: Contribution to journal › Letter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pseudohyperaldosteroism during itraconazole treatment
T2 - a hitherto neglected clinically significant side effect
AU - Brandi, Sandra L.
AU - Feltoft, Claus L.
AU - Serup, Jørgen
AU - Eldrup, Ebbe
N1 - Funding Information: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for- profit sectors. Publisher Copyright: © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023
Y1 - 2023
N2 - We describe a married couple who both presented with hypertension and hypokalaemia. Both patients were diagnosed with pseudohyperaldosteronism triggered by the widely used antifungal drug itraconazole. This effect appears to be dose-dependent, where a daily intake of 100 mg itraconazole is enough to induce pseudohyperaldosteronism. Clinicians should be aware of pseudohyperaldosteronism as a possible adverse effect of itraconazole, and we recommend monitoring potassium levels and blood pressure in all patients receiving this drug over a longer period of time. Voriconazole is probably an alternative antifungal treatment to itraconazole but also with this drug potassium levels should be monitored.
AB - We describe a married couple who both presented with hypertension and hypokalaemia. Both patients were diagnosed with pseudohyperaldosteronism triggered by the widely used antifungal drug itraconazole. This effect appears to be dose-dependent, where a daily intake of 100 mg itraconazole is enough to induce pseudohyperaldosteronism. Clinicians should be aware of pseudohyperaldosteronism as a possible adverse effect of itraconazole, and we recommend monitoring potassium levels and blood pressure in all patients receiving this drug over a longer period of time. Voriconazole is probably an alternative antifungal treatment to itraconazole but also with this drug potassium levels should be monitored.
KW - dermatology
KW - drugs: infectious diseases
KW - endocrinology
KW - hypertension
KW - unwanted effects / adverse reactions
U2 - 10.1136/dtb.2022.243191rep
DO - 10.1136/dtb.2022.243191rep
M3 - Letter
C2 - 36813280
AN - SCOPUS:85138148840
VL - 61
SP - 44
EP - 47
JO - Drug and Therapeutics Bulletin
JF - Drug and Therapeutics Bulletin
SN - 0012-6543
IS - 3
ER -
ID: 396730161